Tenax Therapeutics (TENX) 10% Owner LLC Buys $406K of Stock

ADAR1 Capital Management bought 254,342 shares of Tenax Therapeutics, Inc. (TENX) on October 20, 2026, spending about $405,726. The transaction was disclosed in a Form 4 filing with the SEC.

TENX Tenax Therapeutics, Inc.

$1.63 ▼ -85.25% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside ADAR1 Capital Management's Tenax Therapeutics Trade

The 10% owner acquired the shares at an average price of $1.60, growing its position by a 3.71% increase from the prior count. Following the purchase, the entity holds a total of 7,115,021 shares. The trade was not made pursuant to a pre-arranged Rule 10b5-1 trading plan. The stock recently traded around $1.64 as of October 21, 2026, up about 20.6% since it closed at $1.36 on October 16, 2026.

Other Institutional Activity in Tenax Therapeutics

Other large funds have also adjusted their positions in Tenax Therapeutics recently. Vivo Capital, LLC grew its holdings by 2,291,667 shares, ending with 2,500,000 shares worth about $4,074,999. Perceptive Advisors Llc added 252,206 shares for a 17.4% increase, holding 1,700,000 shares valued at about $2,770,999. Millennium Management Llc increased its stake by 342,334 shares, a 64.1% jump to 876,230 shares worth roughly $1,428,254. Meanwhile, Ikarian Capital, LLC cut its stake by 229,971 shares, or 22.6%, leaving it with 787,600 shares valued at about $1,283,787. Candriam S.C.A. doubled its holding by adding 374,794 shares, ending with 749,588 shares worth about $1,221,828.

Tenax Therapeutics, Inc. Stock Down 13.7%

The company's shares trade on the NasdaqCM under the ticker TENX. The stock recently traded around $1.64 on October 21, 2026, sitting above its close of $1.36 on October 16, 2026.

Recent Earnings

Tenax Therapeutics reported a trailing twelve-month earnings per share of -1.48. The company has a current ratio of 15.07 and a quick ratio of 14.614, alongside a return on equity of -59.8%.

Insider Buying and Selling at Tenax Therapeutics, Inc.

Earlier insider transactions at the company include several purchases leading up to this event. Adar1 Capital Management LLC bought 900,000 shares at $1.78 for a total value of $1,604,160 on September 3, 2026. Chief Financial Officer Thomas R Staab II acquired 5,675 shares at $1.94 on September 11, 2026, worth $10,981. Chief Executive Officer Christopher Thomas Giordano bought 10,850 shares valued at $20,087 on September 15, 2026. Director Declan Doogan purchased 53,000 shares at $1.92 on September 16, 2026, totaling $101,760.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock over recent months. On August 11, 2026, Chardan Capital downgraded the stock to a Neutral rating with a price target of $5.0 ranging down from $27.0. Canaccord Genuity maintained a Buy rating on August 11, 2026, lowering its target to $4.0 from $35.0. Guggenheim maintained a Buy rating on August 11, 2026, with a target of $4.0 down from $40.0, and later downgraded the stock to a Neutral rating on August 31, 2026, without a target. Evercore ISI Group downgraded the stock to an In-Line rating on August 11, 2026, lowering its target to $5.0 from $39.0.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company based in Chapel Hill, North Carolina. The firm focuses on creating novel cardiopulmonary therapies, including phase II clinical trials for treatments targeting pulmonary hypertension and heart failure conditions. Institutional interest and insider trades by major stakeholders like ADAR1 Capital Management reflect ongoing activity around the company's clinical pipeline.

Bottom Line

Investors continue to monitor insider Form 4 filings and upcoming corporate updates from Tenax Therapeutics. Watch for further reports on the firm's drug development progress and future SEC filings from major stakeholders.